COMPANY

Northwest Biotherapeutics

HQ: Bethesda, MD source · nwbio.com ↗ · Mid-Atlantic

Keywords: oncology Prostate Cancer Glioblastoma Multiforme GBM Glioblastoma Grade IV Astrocytoma Glioma Brain Cancer Brain Tumor Brain Metastases Lung Cancer Metastatic Breast Cancer Metastatic Metastatic Solid Tissue Tumors Liver Cancer Colorectal Cancer Pancreatic Cancer Melanoma Dendritic cell immunotherapy DCVax-Direct DCVax-L

Location: Bethesda, MD · source · Oct 14, 2026

Profile checked Oct 10, 2026

$5.0MRaised (2 yrs)5Trials (company is sponsor)5NIH grants

Timeline

Oct 8, 2026 Partnership Partnership / licensing announced Oct 8, 2026. Source: company's own press page. source ↗
Aug 6, 2026 Partnership Partnership / licensing announced Aug 6, 2026. Source: company's own press page. source ↗
Dec 26, 2024 Raise Private placement — Convertible note: $5M (total, as published), announced Dec 26, 2024. Source: company's own press page. source ↗
2018-11 Trial start Phase 1: Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer source ↗
2013-06 Trial start Phase 1/Phase 2: Safety and Efficacy Study of DCVax-Direct in Solid Tumors source ↗
2006-12 Trial start Phase 3: Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer source ↗

Funding

Raised: $5.0M. Last 2 years.

Dec 26, 2024 Private placement — Convertible note: $5M (total, as published), announced Dec 26, 2024. Source: company's own press page. source ↗
Oct 8, 2026 Partnership / licensing announced Oct 8, 2026. Source: company's own press page. source ↗
Aug 6, 2026 Partnership / licensing announced Aug 6, 2026. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT00045968	Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer	Phase 3	Unknown status (ClinicalTrials.gov)	2006-12	2022-11 (estimated)
NCT03638765	Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer	Phase 1	Unknown status (ClinicalTrials.gov)	2018-11	2019-12 (estimated)
NCT02146066	Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221	Not listed	Available	Not listed	Not listed
NCT01882946	Safety and Efficacy Study of DCVax-Direct in Solid Tumors	Phase 1/Phase 2	Unknown status (ClinicalTrials.gov)	2013-06	2016-12 (estimated)
NCT00043212	Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.	Phase 3	Withdrawn	Not listed	Not listed

NIH awards 5

Annual award amounts. Total $946K.

Sep 10, 2004 NIH award 1R43CA103221-01A1 FY2004: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI BOYNTON, ALTON LEE; recipient as written: NORTHWEST BIOTHERAPEUTICS, INC., Bethesda, MD. Improved Reagents for Prosta source ↗
Jan 23, 2004 NIH award 5R01CA057064-11 FY2004: $327,681 awarded for that fiscal year; activity R01 (OTHER_NIH); PI BOYNTON, ALTON L; recipient as written: NORTHWEST BIOTHERAPEUTICS, INC., Bethesda, MD. MEDIATORS OF PLATELET DERIV source ↗
2003 NIH award 7R01CA057064-10 FY2003: $318,137 awarded for that fiscal year; activity R01 (OTHER_NIH); PI BOYNTON, ALTON L; recipient as written: NORTHWEST BIOTHERAPEUTICS, INC., Bethesda, MD. MEDIATORS OF PLATELET DERIV source ↗
Feb 18, 1999 NIH award 1R43CA080398-01 FY1999: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI HOLMES, ERIC; recipient as written: NORTHWEST BIOTHERAPEUTICS, INC., Bethesda, WA. ANTIBODY TARGETING TO PSMA IN PROSTA source ↗
May 27, 1997 NIH award 1R43CA074641-01 FY1997: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI BOYNTON, ALTON L; recipient as written: NORTHWEST BIOTHERAPEUTICS, INC., Bethesda, WA. URINE BASED MOLECULAR TEST FOR P source ↗